54796-51-9

Basic information

• Product Name: Methyl 4-(broMoMethyl)thiophene-2-carboxylate
• Synonyms: Methyl 4-(broMoMethyl)thiophene-2-carboxylate;4-(bromomethyl)-2-Thiophenecarboxylic acid methyl ester;Methyl 4-(bromomethyl)
• CAS NO: 54796-51-9
• Molecular Formula: C₇H₇BrO₂S
• Molecular Weight: 235.09828
• Mol File: 54796-51-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 304.6±32.0 °C(Predicted)
• Appearance: /
• Density: 1.606±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: Methyl 4-(broMoMethyl)thiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(broMoMethyl)thiophene-2-carboxylate(54796-51-9)
• EPA Substance Registry System: Methyl 4-(broMoMethyl)thiophene-2-carboxylate(54796-51-9)

Safety Data

• Hazardous Substances Data: 54796-51-9(Hazardous Substances Data)

Usage

General Description

Methyl 4-(bromomethyl)thiophene-2-carboxylate is a chemical compound with the molecular formula C9H9BrO2S. It is a methyl ester derivative of 4-(bromomethyl)thiophene-2-carboxylic acid, which is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. Methyl 4-(broMoMethyl)thiophene-2-carboxylate has a thiophene ring with a bromomethyl substituent and a carboxylate group attached to it. It is a yellow to light brown liquid with a strong odor and it is mainly used as an intermediate in the production of other organic compounds. Methyl 4-(bromomethyl)thiophene-2-carboxylate has potential applications in the development of new drugs and biologically active molecules.

Upstream product

• 616-44-4 3-Methylthiophene 
• 79-22-1 methyl chloroformate 
• 816449-72-6 4-hydroxymethyl-thiophene-2-carboxylic acid methyl ester 
• 14282-78-1 4-methylthiophene-2-carboxylic acid 
• 28686-90-0 4-methyl-thiophene-2-carboxylic acid methyl ester 

Downstream Products

• 1073242-10-0 C₃₀H₄₅NO₅SSi 

Relevant articles and documents

Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase

Two principal neurotransmitters are involved in the regulation of mammalian neuronal activity, namely, γ-aminobutyric acid (GABA), an inhibitory neurotransmitter, and l-glutamic acid, an excitatory neurotransmitter. Low GABA levels in the brain have been implicated in epilepsy and several other neurological diseases. Because of GABA's poor ability to cross the blood-brain barrier (BBB), a successful strategy to raise brain GABA concentrations is the use of a compound that does cross the BBB and inhibits or inactivates GABA aminotransferase (GABA-AT), the enzyme responsible for GABA catabolism. Vigabatrin, a mechanism-based inactivator of GABA-AT, is currently a successful therapeutic for epilepsy, but has harmful side effects, leaving a need for improved GABA-AT inactivators. Here, we report the synthesis and evaluation of a series of heteroaromatic GABA analogues as substrates of GABA-AT, which will be used as the basis for the design of novel enzyme inactivators.

QUINOXALINES AS B RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.